SAMSCA Drug Patent Profile

Which patents cover Samsca, and what generic alternatives are available?

Samsca is a drug marketed by Otsuka and is included in one NDA. There are two patents protecting this drug and three Paragraph IV challenges.

This drug has eighty-six patent family members in twenty-four countries.

The generic ingredient in SAMSCA is tolvaptan. There are eight drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the tolvaptan profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Samsca

A generic version of SAMSCA was approved as tolvaptan by ALKEM LABS LTD on May 19^th, 2020.

Summary for SAMSCA

International Patents:	86
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	36
Clinical Trials:	37
Patent Applications:	20
Drug Prices:	Drug price information for SAMSCA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SAMSCA
What excipients (inactive ingredients) are in SAMSCA?	SAMSCA excipients list
DailyMed Link:	SAMSCA at DailyMed

See drug prices for SAMSCA

Recent Clinical Trials for SAMSCA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Otsuka Pharmaceutical Vietnam	N/A
Gia Dinh People Hospital	N/A
Chinese Pulmonary Vascular Disease Research Group	N/A

See all SAMSCA clinical trials

Pharmacology for SAMSCA

Drug Class	Vasopressin V2 Receptor Antagonist
Mechanism of Action	Vasopressin V2 Receptor Antagonists

Paragraph IV (Patent) Challenges for SAMSCA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SAMSCA	Tablets	tolvaptan	60 mg	022275	1	2018-03-26
SAMSCA	Tablets	tolvaptan	15 mg	022275	1	2013-10-10
SAMSCA	Tablets	tolvaptan	30mg	022275	1	2013-09-23

US Patents and Regulatory Information for SAMSCA

SAMSCA is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Otsuka	SAMSCA	tolvaptan	TABLET;ORAL	022275-001	May 19, 2009	AB1	RX	Yes	No	8,501,730			Y
Otsuka	SAMSCA	tolvaptan	TABLET;ORAL	022275-002	May 19, 2009	AB1	RX	Yes	Yes	10,905,694		Y
Otsuka	SAMSCA	tolvaptan	TABLET;ORAL	022275-001	May 19, 2009	AB1	RX	Yes	No	10,905,694		Y
Otsuka	SAMSCA	tolvaptan	TABLET;ORAL	022275-002	May 19, 2009	AB1	RX	Yes	Yes	8,501,730			Y
Otsuka	SAMSCA	tolvaptan	TABLET;ORAL	022275-003	May 19, 2009		DISCN	Yes	No	8,501,730			Y
Otsuka	SAMSCA	tolvaptan	TABLET;ORAL	022275-003	May 19, 2009		DISCN	Yes	No	10,905,694		Y

Expired US Patents for SAMSCA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Otsuka	SAMSCA	tolvaptan	TABLET;ORAL	022275-002	May 19, 2009	5,753,677
Otsuka	SAMSCA	tolvaptan	TABLET;ORAL	022275-001	May 19, 2009	5,258,510
Otsuka	SAMSCA	tolvaptan	TABLET;ORAL	022275-003	May 19, 2009	5,258,510
Otsuka	SAMSCA	tolvaptan	TABLET;ORAL	022275-001	May 19, 2009	5,753,677
Otsuka	SAMSCA	tolvaptan	TABLET;ORAL	022275-002	May 19, 2009	5,258,510
Otsuka	SAMSCA	tolvaptan	TABLET;ORAL	022275-003	May 19, 2009	5,753,677

EU/EMA Drug Approvals for SAMSCA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Otsuka Pharmaceutical Netherlands B.V.	Jinarc	tolvaptan	EMEA/H/C/002788Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.	Authorised	no	no	no	2015-05-27
Otsuka Pharmaceutical Netherlands B.V.	Samsca	tolvaptan	EMEA/H/C/000980Treatment of adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic-hormone secretion (SIADH).,	Authorised	no	no	no	2009-08-02
Accord Healthcare S.L.U.	Tolvaptan Accord	tolvaptan	EMEA/H/C/005961Tolvaptan is indicated in adults for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH).	Authorised	yes	no	no

International Patents for SAMSCA

When does loss-of-exclusivity occur for SAMSCA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

China

Cyprus

Denmark

Hong Kong

Israel

Japan

Poland

Slovenia

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SAMSCA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	067077
Austria	E489944
Australia	2008264445
Brazil	PI0813100
Canada	2689467
China	101686941
China	103463095

Supplementary Protection Certificates for SAMSCA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0450097	CA 2009 00031	Denmark
0450097	SPC/GB09/037	United Kingdom		PRODUCT NAME: TOLVAPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/09/539/001 20090803; UK EU/1/09/539/002 20090803; UK EU/1/09/539/003 20090803; UK EU/1/09/539/004 20090803
0450097	300408	Netherlands		300408, 20101018, EXPIRES: 20151017
0450097	09C0049	France		PRODUCT NAME: TOLVAPTAN, EVENTUELLEMENT SOUS FORME DE SEL; REGISTRATION NO/DATE: EU/1/09/539/001 20090803
0450097	C300408	Netherlands		PRODUCT NAME: TOLVAPTAN, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/09/539/001-004 20090803

SAMSCA (tolvaptan) Market Dynamics and Financial Trajectory: Exclusivity Timeline, Patent/Generic Threats, and Revenue Exposure

Last updated: June 30, 2026

Executive summary: SAMSCA (tolvaptan) generated significant early revenue but has faced persistent erosion from generic entry risk, shifting prescribing patterns, and constrained use cases for hyponatremia. The drug’s U.S. financial trajectory is characterized by peak commercialization followed by long-run decline after loss of effective exclusivity and the emergence of lower-cost alternatives. For investors and licensing teams, the core question is not near-term “new launches” but how much remaining brand revenue persists amid durable price pressure, prescriber conservatism, and contracting formularies, while the underlying patent estate limits generic or label-expansion opportunities.

---

What is SAMSCA (tolvaptan) used for and why does that shape market uptake?

Featured snippet answer: SAMSCA is a vasopressin V2 receptor antagonist used to increase serum sodium in hospitalized patients with clinically significant hypervolemic or euvolemic hyponatremia, including cases resistant to fluid restriction.

Which clinical indications drive demand

SAMSCA’s commercial footprint is tied to narrow, label-based hyponatremia use in inpatient settings. This creates a market that is:

• concentrated in acute care workflows (hospital formularies, nephrology and inpatient medicine)
• sensitive to guideline alignment and local protocol adoption
• exposed to substitution to alternative hyponatremia strategies (fluid restriction, hypertonic saline, loop diuretics, and institutional protocols)

How administration and monitoring requirements affect prescribing

Tolvaptan requires serum sodium monitoring due to risk of overly rapid correction and related adverse outcomes. That monitoring burden:

• shifts adoption to sites with established hyponatremia pathways
• reduces “walk-in” outpatient uptake
• increases friction versus less monitoring-intensive interventions

Endpoint-driven demand volatility

Sustained reimbursement depends on real-world outcomes tied to faster or safer sodium correction. Any evidence or clinician experience that reduces perceived incremental benefit against standard of care tends to translate into reduced formulary pull.

---

How has SAMSCA’s revenue trajectory changed over time?

Featured snippet answer: SAMSCA’s financial trajectory shows a classic pattern for a specialty hospital drug: high launch ramp and peak performance followed by sustained decline as effective exclusivity diminished and price competition and clinical substitution increased.

Key phases of the SAMSCA commercial cycle

1. Launch and scaling phase
   • Uptake grows via inpatient adoption, early KOL influence in nephrology and hospitalists, and guideline uptake.
2. Maturity phase
   • Peak revenue coincides with stable formulary positions and steady inpatient volumes for hyponatremia.
3. Erosion phase
   • Brand revenue declines as:
     • lower-cost alternatives compress reimbursement
     • contracting formularies reduce preferred status
     • prescribing shifts to institution-specific pathways
     • generic substitution becomes feasible where legal barriers fall

What matters most to quarterly revenue

For SAMSCA, revenue is driven less by total number of hyponatremia patients and more by:

• proportion of eligible patients managed with tolvaptan instead of institutional alternatives
• formulary placement and usage protocols
• managed care contracting and hospital pharmacy pricing

---

When does SAMSCA lose exclusivity, and what timeline risks generics?

Featured snippet answer: The generic threat is driven by patent expiry for tolvaptan and any formulation, method-of-use, or label-protection patents that may extend market exclusivity. Once those barriers clear, FDA-approved generics can enter unless a remaining Orange Book-listed patent blocks them through litigation or settlement.

Exclusivity as a stack, not a single date

For a branded hospital drug, the timeline risk is not “one patent, one expiry.” It is the interaction among:

• composition-of-matter patent expiry
• method-of-use and dosing regimen patents (if any remain listed)
• formulation and manufacturing patents (if they cover practical commercial products)
• litigation status (including consent judgments and settlements)

Practical investor read

If the Orange Book estate is thin by the late-cycle period, the generics risk concentrates into a narrower window, with revenue decline accelerating post-barrier clearance.

---

What patents protect SAMSCA tolvaptan, and how strong is the patent estate?

Featured snippet answer: SAMSCA’s patent protection is defined by Orange Book-listed patents covering tolvaptan and any downstream formulation or method-of-use protections that remain enforceable at the time of generic submissions.

How to map the SAMSCA patent stack to market exposure

To assess strength, licensing and litigation teams track four layers:

• Composition of matter: usually earlier filing dates, often long expired by the late lifecycle.
• Formulation: can extend the practical barrier if it covers the marketed dosage form or specific release/combination attributes.
• Method of use: may protect the approved hyponatremia clinical use and monitoring approach.
• Manufacturing process: can block certain generic manufacturing routes.

Why patent strength still matters even after generic entry

Even after generic launch, residual brand revenue can persist if:

• hospital formularies remain favorable to the brand
• patient-specific clinical reasons limit substitution
• contracting and rebate economics delay full price parity

But weak Orange Book coverage shortens the runway for continued premium pricing.

---

How many patents cover SAMSCA in the FDA Orange Book, and what are their expiration dates?

Featured snippet answer: The number of listed patents and their expiration dates determine the time window for Paragraph IV challenges and the risk of generic entry. Orange Book data is the operational artifact for this analysis.

Operational method to evaluate exposure

A high-integrity evaluation for SAMSCA focuses on:

• whether multiple patents share the same expiry date (creating “cliff risk”)
• whether staggered expirations create a longer period of incremental erosion
• whether any patents remain in force later than the last composition-of-matter expiry

Commercial consequence

• A dense cluster of Orange Book expiries increases the chance of a near-simultaneous generic entry and faster revenue decline.
• A sparse estate often yields fewer challenges but also less ability to prevent early entry.

(Orange Book identification requires the specific Orange Book listing set for SAMSCA.)

---

What generic entry risks exist for SAMSCA under Paragraph IV?

Featured snippet answer: Paragraph IV filings target Orange Book-listed patents. Generic entry risk peaks when the remaining enforceable patents are few, thin, or unlikely to survive litigation.

How Paragraph IV affects pricing and volume

When generics enter:

• average selling prices compress quickly
• brand volume declines as substitution becomes routine
• hospital pharmacy purchasing shifts toward lower acquisition cost
• wholesalers reduce brand inventory

Litigation outcomes and settlement timing

Even where litigation blocks immediate entry, settlements can trigger “at-risk” launch dates. The revenue-impact question is not only “who wins,” but “when does the settlement allow launch.”

---

Which companies are challenging SAMSCA patents or attempting to launch generics?

Featured snippet answer: The practical market-risk set is the set of Paragraph IV filers and their parent companies, plus any authorized generic strategies. This determines the speed and depth of price erosion.

Market implication

A larger set of ANDA challengers increases competitive intensity and can reduce time-to-price parity.

(A precise list depends on the Orange Book ANDA/Paragraph IV filing history and court dockets tied to SAMSCA.)

---

What patent litigation affects SAMSCA, and how do settlements change launch timing?

Featured snippet answer: Patent litigation impacts SAMSCA by determining whether generic products can market at full expiry or are delayed by injunctions, stays, or settlement-triggered launch dates.

Settlement structure that matters commercially

Settlements frequently include:

• agreed effective date for generic launch
• license scope for formulation or use parameters
• payment and dismissal terms (which affect both timing and incentives)

The market-level effect is the effective generic “switch date,” which governs revenue decline velocity.

---

What is the FDA regulatory status of SAMSCA (tolvaptan), and how does it affect market competition?

Featured snippet answer: SAMSCA’s regulatory status governs the reference product for generics and any potential label changes that could affect “skinny label” substitution.

Why label scope influences substitution

If the brand’s label is narrow and monitoring-heavy, generics that attempt partial label coverage may face:

• reduced uptake (clinicians follow the exact label)
• payer or formulary restrictions tied to specific contraindications and monitoring parameters
• downstream risk of post-marketing label divergence

Hospital drug adoption is procedural

Even with generic approval, hospitals may use protocols that reduce substitution if clinical teams prefer a brand with robust product support.

---

How does SAMSCA compare with alternative hyponatremia treatments in cost and adoption?

Featured snippet answer: Adoption depends on perceived incremental benefit versus standard hyponatremia care and the administrative burden of monitoring. Cost pressure shifts preference to lower total-cost alternatives once generic tolvaptan is available.

Competitive set

SAMSCA competes with:

• fluid restriction protocols (especially for mild or non-severe cases)
• hypertonic saline approaches (with monitoring and risk management)
• loop diuretics and other institutional strategies
• other vasopressin-pathway approaches, where available and relevant to label

Why generic tolaptan still competes with brand tolaptan

Once generic tolaptan is available, the clinical “product” becomes less differentiated, and procurement drives substitution unless branding delivers meaningful workflow support.

---

What formulations are protected for SAMSCA, and do they block generic manufacturing?

Featured snippet answer: Formulation or manufacturing patents block generic entry only if they cover the marketed dosage form and impose constraints that generics cannot easily design around.

Manufacturing/IP barriers that affect timelines

If a formulation patent remains enforceable:

• generics may need design-around or licensing
• launch may be delayed pending clearance of patent issues
• authorized generics may emerge to manage risk

---

How does SAMSCA’s market access vary across geography and payer mix?

Featured snippet answer: In many markets, SAMSCA-like hospital drugs experience slower uptake outside leading inpatient systems because hyponatremia management is protocol-driven and varies by guideline adoption and monitoring infrastructure.

What shifts cross-market performance

• hospital formulary tiering
• reimbursement rules for inpatient drugs
• clinical pathway maturity for hyponatremia and sodium correction monitoring
• availability of low-cost alternatives and generics

---

What is the current commercial outlook for SAMSCA amid price erosion?

Featured snippet answer: The current outlook is dominated by late-cycle brand dynamics: continued price pressure from generics and hospital formulary tightening outweigh potential incremental growth from new prescriber adoption.

Revenue levers that can still matter late-cycle

• pharmacy contracting strategies and rebate positioning
• brand-specific support services for inpatient management protocols
• evidence generation that reinforces clinical preference in specific subgroups
• restricted substitution policies in some systems

Revenue headwinds that persist

• generic price anchoring
• reduction in brand differentiation
• high monitoring burden that makes protocols “standardized” once generics exist

---

Key Takeaways

• SAMSCA’s market is inherently narrow, inpatient-focused, and protocol-driven, which limits long-term growth after maturity.
• The financial trajectory is shaped by the timing of Orange Book barrier clearance and generic substitution, not by new indication expansion.
• Patent estate strength and litigation outcomes determine the “switch date” for generic price erosion, which then drives sustained brand revenue decline.
• Late-cycle performance is governed by payer and hospital contracting dynamics and whether clinicians maintain brand preference after generic tolaptan availability.

---

FAQs

1) What drives SAMSCA hospital formulary adoption?
Inpatient sodium-correction protocols, clinician confidence in monitoring and correction speed, and contracting economics versus alternative hyponatremia interventions.

2) Does generic tolvaptan reduce SAMSCA revenue only after patent expiry?
Generic tolvaptan affects revenue as soon as substitution becomes operational via pricing, contracting, and protocol update timelines, which can lag legal clearance.

3) Can method-of-use or formulation patents extend SAMSCA brand sales after composition-of-matter expiry?
Only if Orange Book-listed method-of-use or formulation patents remain enforceable and cover practical routes or label-relevant use that generics cannot easily design around.

4) What risks matter for licensing a SAMSCA-related product or process?
The enforceability window of Orange Book patents tied to tolvaptan dosage form, plus any ongoing litigation or settlement-triggered launch dates.

5) How does monitoring risk management influence SAMSCA competitive position?
Monitoring burden can reduce adoption where protocols are conservative, but once established, standardized pathways may accelerate substitution to the lowest-cost equivalent.

---

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
2. FDA Labeling for SAMSCA (tolvaptan). U.S. prescribing information database. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm

DrugChatter Q&A for SAMSCA

Does samsca has generic form?
How much does samsca cost?
Why is samsca so expensive?